Written before stock split

This narrative hasn't been updated since the stock split on 18 Jun 2026. The author has been notified to update.

Published

20 Apr 25

Updated

20 Nov 25

Views

68

Not Invested

Allurion TechnologiesALUR

Fair Value

US$7

Share price20 Nov

US$1.9572.1% undervalued

Loading

1Y-93.47%

7D-44.29%

Expanding Obesity Solutions Will Boost Prospects Amid Launch Uncertainties

AN

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

20 Apr 25

Updated

20 Nov 25

Views

68

Not Invested

Shared on 20 Nov 25

Fair value Increased 20%

ALUR: Expanded Brazil Hospital Network Will Drive Obesity Therapy Access

Narrative Update on Allurion Technologies: Analyst Price Target Revision Analysts have raised their price target for Allurion Technologies from $5.83 to $7.00. They cite improved revenue growth projections and a slight uplift in expected profit margin as the primary factors behind the upward revision.

3 views

Shared on 24 Sep 25

Fair value Decreased 30%

A significant reduction in consensus revenue growth forecasts has driven the analyst price target for Allurion Technologies down from $8.38 to $5.83. What's in the News Allurion Technologies was unable to file its next 10-Q by the required SEC deadline.

4 views

Shared on 15 Aug 25

With consensus forecasts for both revenue growth and net profit margin remaining steady, analysts have left their fair value estimate for Allurion Technologies unchanged at $8.38. What's in the News Allurion Technologies announced a strategic Canadian distribution partnership with Minogue Medical Inc., leveraging Minogue's national network of obesity care providers to expand access to Allurion's metabolically healthy weight loss program.

8 views

Shared on 01 May 25

Fair value Decreased 21%

3 views

Shared on 24 Apr 25

4 views

Fair Value vs Share Price

US$7

vs US$1.9572.1% undervalued

54.3%

Revenue growth

12.4%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Allurion Technologies

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Moderate risk and slightly overvalued.

Market capUS$2.3m

PB-0.0x

Estimated GrowthN/A

Dividend YieldN/A

CEO & management

Shantanu Gaur

CEO

2.6yrs

CEO Tenure

Focuses on developing a weight loss platform for overweight people in Spain, France, Turkey, and internationally.